Key result
Age over 65 is linked to ~180% greater bleeding risk in warfarin-treated patients.
Why the study?
Bleeding is the most frequent and restrictive complication of warfarin therapy, and the study aimed to compare bleeding risk factors between patients with and without warfarin-related bleeding.
What are the clinical and demographic risk factors associated with warfarin-related bleeding?
Population
201 warfarin-treated outpatient clinic patients
Comparison
Patients with bleeding during warfarin use vs those followed up without bleeding
Design
Questionnaire-based study
Authors
Loading...
May support closer monitoring of older warfarin patients with comorbidities; leaves open prospective validation in larger cohorts.
Case-Control (n=201)
No
What are the clinical and demographic risk factors associated with warfarin-related bleeding?
Effect estimate: OR 2.8 (95% CI 1.409-5.563)
Absolute Event Rate: 67% vs 53.47%
p-value: p=0.05
Age over 65, presence of comorbid diseases, history of stroke, and lower education level are significant risk factors for warfarin-associated bleeding, highlighting the need for targeted monitoring and patient education.
Özgenel et al. (2023) conducted a case-control in Warfarin-associated bleeding (n=201). Age ≥65 years vs. Age <65 years was evaluated on Warfarin-associated bleeding (OR 2.8, 95% CI 1.409-5.563, p=0.05). In patients treated with warfarin, being 65 years of age or older and having comorbid diseases increased the risk of bleeding by 2.8-fold and 5.6-fold, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: